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Abstract Attention deficit hyperactivity disorder (ADHD) is among the most frequent disorders
within child and adolescent psychiatry, with a prevalence of over 5%. Nosological
systems, such as the Diagnostic and Statistical Manual of Mental Disorders, 5th edition
(DSM-5) and the International Classification of Diseases, editions 10 and 11 (ICD-10/11)
continue to define ADHD according to behavioral criteria, based on observation and on
informant reports. Despite an overwhelming body of research on ADHD over the last 10
to 20 years, valid neurobiological markers or other objective criteria that may lead to
unequivocal diagnostic classification are still lacking. On the contrary, the concept of
ADHD seems to have become broader and more heterogeneous. Thus, the diagnosis
and treatment of ADHD are still challenging for clinicians, necessitating increased
reliance on their expertise and experience. The first part of this review presents an
overview of the current definitions of the disorder (DSM-5, ICD-10/11). Furthermore, it
discusses more controversial aspects of the construct of ADHD, including the
dimensional versus categorical approach, alternative ADHD constructs, and aspects
pertaining to epidemiology and prevalence. The second part focuses on comorbidities,
on the difficulty of distinguishing between “primary” and “secondary” ADHD for
purposes of differential diagnosis, and on clinical diagnostic procedures. In the third
and most prominent part, an overview of current neurobiological concepts of ADHD is
given, including neuropsychological and neurophysiological researches and summaries
of current neuroimaging and genetic studies. Finally, treatment options are reviewed,
including a discussion of multimodal, pharmacological, and nonpharmacological
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With a prevalence of over 5%, attention deficit hyperactivity
disorder (ADHD) is one of themost frequent disorders within
child and adolescent psychiatry. Despite an overwhelming
body of research, approximately 20,000 publications have
been referenced in PubMed during the past 10 years, assess-
ment and treatment continue to present a challenge for
clinicians. ADHD is characterized by the heterogeneity of
presentations, which may take opposite forms, by frequent
and variable comorbidities and an overlap with other dis-
orders, and by the context-dependency of symptoms, which
may or may not become apparent during clinical examina-
tion.While the neurobiological and genetic underpinnings of
the disorder are beyond dispute, biomarkers or other objec-
tive criteria, which could lead to an automatic algorithm for
the reliable identification of ADHD in an individual within
clinical practice, are still lacking. In contrast to what one
might expect after years of intense research, ADHD criteria
defined by nosological systems, such as the Diagnostic and
Statistical Manual of Mental Disorders, 5th edition (DSM-5)
and the International Classification of Diseases, editions 10
and 11 (ICD-10/11) have not become narrower and more
specific. Rather, they have become broader, for example,
encompassing wider age ranges, thus placingmore emphasis
on the specialist’s expertise and experience.1–3
Definitions and Phenomenology
ADHD According to the DSM-5 and ICD-10/11
ADHD is defined as a neurodevelopmental disorder. Its diag-
nostic classification is based on the observation of behavioral
symptoms. ADHD according to the DSM-5 continues to be a
diagnosis of exclusion and should not be diagnosed if the
behavioral symptoms can be better explained by other mental
disorders (e.g., psychotic disorder, mood or anxiety disorder,
personality disorder, substance intoxication, or withdrawal).1
However, comorbiditywithothermentaldisorders is common.
In the DSM-5, the defining symptoms of ADHD are divided
into symptoms of inattention (11 symptoms) and hyper-
activity/impulsivity (9 symptoms).1The formerdifferentiation
between subtypes in the DSM-IV proved to be unstable and to
depend on the situational context, on informants, or on
maturation, and was therefore replaced by “presentations.”4
Thus, the DSM-5 distinguishes between different presenta-
tions of ADHD: predominantly inattentive (6 or more out of
11 symptoms present), predominantly hyperactive/impulsive
(6 ormore out of 9 symptomspresent), and combined presen-
tation (both criteria fulfilled), as well as a partial remission
category. Symptomshave tobepresent in twoormore settings
before the age of 12 years for at least 6 months and have to
reduceor impair social, academic, or occupational functioning.
In adolescents over 17 years and in adults, five symptoms per
dimension need to be present for diagnosis.1 In adults, the use
of validated instruments like the Wender Utah rating scale is
recommended.5
In contrast, the ICD-10 classification distinguishes be-
tween hyperkinetic disorder of childhood (with at least six
symptoms of inattention and six symptoms of hyperactivity/
impulsivity, present before the age of 6 years) and hyperki-
netic conduct disorder, a combination of ADHD symptoms
and symptoms of oppositional defiant and conduct disorders
(CD).3 In the ICD-11 (online release from June 2018, printed
release expected 2022), the latter category has been
dropped, as has the precise age limit (“onset during the
developmental period, typically early to mid-childhood”).
Moreover, the ICD-11 distinguishes five ADHD subcatego-
ries, which match those of the DSM-5: ADHD combined
presentation, ADHD predominantly inattentive presenta-
tion, ADHD predominantly hyperactive/impulsive presenta-
tion and two residual categories, ADHD other specified and
ADHD nonspecified presentation. For diagnosis, behavioral
symptoms need to be outside the limits of normal variation
expected for the individual’s age and level of intellectual
functioning.2
Overlapping Constructs: Sluggish Cognitive Tempo
and Emotional Dysregulation
Sluggish cognitive tempo (SCT) is a clinical construct charac-
terized by low energy, sleepiness, and absent-mindedness,
and is estimated to occur in 39 to 59% of (adult) individuals
with ADHD.6,7 The question of whether SCTmight constitute
a feature of ADHD or a separate construct that overlaps with
ADHD inattention symptoms is unresolved.8 While current
studies indicate that SCT might be distinct and independent
from hyperactivity/impulsivity, as well as from inattention
dimensions, it remains uncertain whether it should be
considered as a separate disorder.8,9 Twin studies have
revealed a certain overlap between SCT andADHD, especially
with regard to inattention symptoms, but SCT seems to be
more strongly related to nonshared environmental factors.10
Emotion dysregulation is another associated feature that
has been discussed as a possible core component of child-
hood ADHD, although it is not included in the DSM-5 criteria.
Deficient emotion regulation is more typically part of the
symptom definition of other psychopathological disorders,
such as oppositional defiant disorder (ODD), CD, or disrup-
tive mood dysregulation disorder (DSM-5; for children up to
8 years).11 However, an estimated 50 to 75% of children with
ADHD also present symptoms of emotion dysregulation, for
example, anger, irritability, low tolerance for frustration, and
outbursts, or sometimes express inappropriate positive
emotions. The presence of these symptoms increases the
risk for further comorbidities, such as ODD and also for
anxiety disorders.12,13 For adult ADHD, emotional irritability
is a defining symptom according to theWender Utah criteria,
and has been confirmed as a primary ADHD symptom by
several studies (e.g., Hirsch et al).5,14,15
Whether emotion dysregulation is inherent to ADHD,
applies to a subgroupwith combined symptomsanda singular
neurobiological pathway, or is comorbidwithbut independent
of ADHD, is still a matter of debate (for a description of these
threemodels; Shawet al13). Faraoneet al12distinguished three
ADHDprototypeswith regard todeficient emotion regulation:
ADHD prototype 1 with high-emotional impulsivity and defi-
cient self-regulation, prototype 2 with low-emotional
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impulsivityanddeficient self-regulation, andprototype3with
high-emotional impulsivity and effective self-regulation. All
three prototypes are characterized by an inappropriate inten-
sity of emotional response. While prototypes 1 and 3 build up
their responses very quickly, prototype 2 is slower to respond
but experiences higher subjective emotional upheaval than is
overtly shown in the behavior. Prototypes 1 and 2 both need
more time to calm down comparedwith prototype 3 inwhich
emotional self-regulation capacities are intact.
Dimensional versus Categorical Nature of ADHD
Recent research on subthreshold ADHD argues in favor of a
dimensional rather than categorical understanding of the
ADHD construct, as its core symptoms and comorbid features
are dimensionally distributed in the population.16–18 Sub-
threshold ADHD is common in the population, with an
estimated prevalence of approximately 10%.19 According to
Biederman and colleagues, clinically referred children with
subthreshold ADHD symptoms show a similar amount of
functional deficits and comorbid symptoms to thosewith full
ADHD, but tend to come from higher social-class families
with fewer family conflicts, to have fewer perinatal compli-
cations, and to be older and female (for the latter two, a
confound with DSM-IV criteria cannot be excluded).20
Temperament and Personality Approaches to ADHD
Another approachwhich is in accordancewith a dimensional
concept is to analyze ADHD and categorize subtypes accord-
ing to temperament/personality traits (for a review and the
different concepts of temperament see Gomez and Corr21).
Temperament/personality traits are usually defined as neu-
robiologically based constitutional tendencies, which deter-
mine how the individual searches for or reacts to external
stimulation and regulates emotion and activity. While tem-
perament traits per se are not pathological, extreme varia-
tions or specific combinations of traits may lead to
pathological behavior. This approach has been investigated
in several studies by Martel and colleagues and Nigg,22–24
who employed a temperament model comprising three
empirically derived domains25,26: (1) negative affect, such
as tendencies to react with anger, frustration, or fear; (2)
positive affect or surgency which includes overall activity,
expression of happiness, and interest in novelty; and (3)
effortful control which is related to self-regulation and the
control of action. The latter domain shows a strong overlap
with the concept of executive function.27 In a community
sample, early temperamental traits, especially effortful con-
trol and activity level, were found to potentially predict later
ADHD.28 Karalunas et al29,30 distinguished three tempera-
ment profiles in a sample of children with ADHD: one with
normal emotional functioning; one with high surgency,
characterized by high levels of positive approach-motivated
behaviors and a high–activity level; and one with high
negative (“irritable”) affect, with the latter showing the
strongest, albeit only moderate stability over 2 years. Irrita-
bility was not reducible to comorbidity with ODD or CD and
was interpreted as an ADHD subgroup characteristic with
predictive validity for an unfavorable outcome. These ADHD
temperament types were distinguished by resting-state and
peripheral physiological characteristics as measured by
functional magnetic resonance imaging (fMRI).29
Epidemiology and Prevalence
While ADHD seems to be a phenomenon that is encountered
worldwide,31 prevalence rates and reported changes in
prevalence are highly variable, depending on country and
regions, method, and sample.32 A meta-analysis by Polanc-
zyk et al32 yielded a worldwide prevalence rate of 5.8% in
children and adolescents.33 In an update published 6 years
later, the authors did not find evidence for an increase in
prevalence over a time span of 30 years. Othermeta-analyses
reported slightly higher (e.g., 7.2%)34 or lower prevalence
rates, which seems to be attributable to the different criteria
adopted for defining ADHD. Prevalence rates in children and
adolescents represent averaged values across the full age
range, but peak prevalence may be much higher in certain
age groups, for example, 13% in 9-year-old boys.35 Universal
ADHD prevalence in adults is estimated to lie at 2.8%, with
higher rates in high-income (3.6%) than in low-income (1.4%)
countries.36 True prevalence rates (also called community
prevalence, e.g., Sayal et al37) should be based on population-
based representative health surveys, that is, the actual base
rate of ADHD in the population, in contrast to the adminis-
trative base rate, which is related to clinical data collection
(Taylor38). Recent reports on the increase in ADHD rates
usually refer to administrative rates, drawn from health
insurance companies, from the number of clinical referrals
for ADHD,39 clinical case identification estimates, or from the
percentage of children taking stimulant medication (pre-
scription data). Changes in these rates may be influenced by
increased awareness, destigmatization, modifications in the
defining criteria of ADHD, or altered medical practice.
According to a recent U.S. health survey on children and
adolescents (4–17 years), in which parents had to indicate
whether their child had ever been diagnosedwith ADHD, the
percentage of diagnoses increased from6.1% in 1997 to 10.2%
in 2016.40 A representative Danish survey based on health
registry, data collected from 1995 to 2010 reported that
ADHD incidence rates increased by a factor of approximately
12 (for individuals aged 4–65 years) during this period.
Moreover, the gender ratio decreased from 7.5:1 to 3:1 at
early school age and from 8.1:1 to 1.6:1 in adolescents in the
same time frame,41,42 probably indicating an improved
awareness of ADHD symptoms in girls. In other countries,
it is assumed that girls are still underdiagnosed.38
Population register data show that the use of stimulants
for ADHD has increased considerably worldwide.43 In most
countries, an increase in stimulant medication use has been
observed in children since the 1990s (e.g., United Kingdom
from 0.15% in 1992 to 5.1% in 2012/2013),44,45 but in some
European countries, stimulant prescription rates for children
and adolescents have remained stable or decreased over the
last 5 to 10 years (e.g., Germany).35 In the United States, the
prescription of methylphenidate peaked in 2012 and has
since been slightly decreasing, while the use of amphet-
amines continues to rise.46
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Comorbidity, Differential Diagnosis, and
Clinical Assessment
Comorbidity
ADHD is characterized by frequent comorbidity and overlap
with other neurodevelopmental and mental disorders of
childhood and adolescence. The most frequent comorbidities
are learning disorders (reading disorders: 15–50%,4 dyscalcu-
lia: 5–30%,47 autism spectrum disorder, which since the DSM-
5 is no longer viewed as an exclusion criterion for ADHD
diagnosis: 70–85%,48,49 tic/Tourette’s disorder and obsessive
compulsive disorder: 20%, and 5%,50 developmental coordina-
tion disorder: 30–50%,51 depression and anxiety disorders: 0–
45%,52,53andODDandCD:27–55%54). ADHD increases the risk
of substance misuse disorders 1.5-fold (2.4-fold for smoking)
and problematic media use 9.3-fold in adolescence55,56 and
increases the risk of becoming obese 1.23-fold for adolescent
girls.57–59 It is also associatedwith different forms of dysregu-
lated eating in children and adolescents. Enuresis occurs in
approximately 17% of children with ADHD,60 and sleep dis-
orders in 25 to 70%.61 Frequent neurological comorbidities of
ADHD include migraine (about thrice more frequent in ADHD
than in typically developing [TD] children)62–64 and epilepsy
(2.3 to thricemore frequent in ADHD than inTD children).65,66
The risk of coexisting ADHD being seen as a comorbid condi-
tionandnot theprimarydiagnosis is considerablyenhanced in
manychildhooddisordersofdifferentorigins. For example, the
rate of comorbid ADHD is estimated at 15 to 40%67,68 in
children with reading disorders and at 26 to 41%69,70 in
childrenwithmild intellectual dysfunction.While comorbidi-
ty in neurodevelopmental disorders may arise from a certain
genetic overlap (see details under genetic associations), ADHD
symptoms are also present in several disorders with well-
known and circumscribed genetic defects, normally not relat-
ed to ADHD (e.g., neurofibromatosis, Turner’s syndrome, and
Noonan’s syndrome)71 or disorders with nongenetic causes,
such as traumatic brain injuries, pre-, peri- or postnatal stroke,
or syndromes due to toxic agents, such as fetal alcohol syn-
drome. Comorbid ADHD is estimated in 20 to 50% of children
with epilepsy,72,73 in 43% of children with fetal alcohol syn-
drome,74 and in 40% of children with neurofibromatosis I.75
ADHD is three times more frequent in preterm-born children
than in children born at term and four times more frequent in
extremely preterm-born children.76
Differential Diagnosis, Primary and Secondary ADHD
A range ofmedical andpsychiatric conditions show symptoms
that are also present in primary ADHD. The most important
medical conditions which are known to “mimic” ADHD and
need to be excluded during the diagnostic process are epilepsy
(especially absence epilepsy and rolandic epilepsy), thyroid
disorders, sleep disorder, drug interaction, anemia, and leu-
kodystrophy.77,78 The most important psychiatric conditions
to be excluded are learning disorder, anxiety disorders, and
affective disorders, while an adverse home environment also
needs to be excluded.
However, the picture is complex, as many differential
diagnoses may also occur as comorbidities. For instance,
bipolar disorder, which is frequently diagnosed in children
and adolescents in the United States but not in Europe, is
considered as a differential diagnosis to ADHD, but ADHD has
also been found to be a comorbidityof bipolardisorder in 21 to
98% of cases.79 Similarly, absence epilepsy is a differential
diagnosis of ADHD but is also considered to be a frequent
comorbidity, occurring in 30 to 60% of children with absence
epilepsy.80 The prevalence of the ADHD phenotype in benign
childhood epilepsy with centrotemporal spikes (rolandic epi-
lepsy) lies at 64 to 65%,81 and is possibly related to the
occurrence of febrile convulsions.82 The literature often does
not draw a clear distinction between an ADHD phenotype,
which includesall typesofetiologies andcauses, andayet tobe
specified developmental ADHD “genotype.” Some authors use
terms, such as “idiopathic”ADHD,83 “primary,” or “genotypic”
ADHD,84 in contrast to ADHD of circumscribed origin other
than developmental, the latter being referred to as ADHD
“phenotype,” or “phenocopy,”85 or “ADHD-like.”86 “Secondary
ADHD” usually refers to newly acquired ADHD symptoms
arising after a known event or incident, for example, a head
trauma or stroke. After early childhood stroke, the ADHD
phenotype occurs in 13 to 20% of cases, and after pediatric
traumatic brain injury, ADHD symptoms are observed in 15 to
20% of children.87 Having ADHD considerably increases the
riskof sufferinga traumatic brain injury,88–90 andmost studies
on secondary ADHD after traumatic brain injury control for or
comparewithpremorbidADHD(e.g., Ornsteinet al91).Wheth-
er and to what extent “phenotypic” and “genotypic” ADHD
need to be distinguished on a phenomenological level is not
clear. It is possible that shared neurobiological mechanisms
will prevail and that genetic vulnerability and epigenetic
factors may play a role in both types. For example, James
et al86 compared neurophysiological markers in two groups of
adolescents with ADHD, one born very preterm and the other
born at term. While the authors found very similar ADHD-
specific markers in the two groups, some additional deficits
only emerged in the preterm group, indicating more severe
impairment. Other examples are rare genetic diseases with
known genetic defects, which are often comorbidwith ADHD.
One may ask whether, for example, ADHD in Turner’s syn-
drome should be considered as a rare genetic ADHD variant
and count as genotypic ADHD, or whether it results from a
different genetic etiology, with the status of an ADHD
phenotype.
Clinical Diagnostic Procedure
Clinical assessment in children should mainly be based on a
clinical interview with parents, including an exploration of
the problems, the detailed developmental history of the child
includingmedical or psychiatric antecedents, information on
family functioning, peer relationships, and school history.
According to the guidelines of the National Institute for
Health and Care Excellence (NICE) in the United Kingdom,
thismayalso include information on themental health of the
parents and the family’s economic situation. The child’s
mental state should be assessed, possibly using a standard-
ized semistructured clinical interview containing ADHD
assessments (e.g., Kiddie Schedule for Affective Disorders
Neuropediatrics
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and Schizophrenia Present and Lifetime version, DSM-5)92,93
and by observer reports. The exploration should cover be-
havioral difficulties and strengths in several life contexts, for
example, school, peer relationships, and leisure time. The use
of informant rating scales, such as Conners’ Rating Scales, 3rd
edition,94 or the Strengths and Difficulties Questionnaire95
may be useful, but diagnosis should not be solely based on
rating scales (NICE, AWFM ADHD).96,97 A further interview
should be conducted with the child or adolescent to gain a
picture of the patient’s perspective on current problems,
needs, and goals, even though self-reports are considered
less reliable for diagnosis. Information should also be
obtained from the school, for example, by face-to-face or
telephone contact with the teacher and, if possible, by direct
school-based observation. A medical examination should be
performed to exclude somatic causes for the behavioral
symptoms and to gain an impression of the general physical
condition of the patient. Current guidelines do not recom-
mend including objective test procedures (intelligence and
neuropsychological tests), neuroimaging, or neurophysio-
logical measures in routine ADHD assessment but do suggest
their use as additional tools when questions about cognitive
functions, academic problems, coexisting abnormalities in
electroencephalography (EEG), or unrecognized neurologi-
cal conditions arise. After completion of the information
gathering, the NICE guidelines recommend a period of
“watchful waiting” for up to 10 weeks before delivering a
formal diagnosis of ADHD. A younger age of the diagnosed
child relative to his/her classmates has to be mentioned as
one of the many pitfalls in the assessment of ADHD. It has
been shown that the youngest children in a class have the
highest probability of being diagnosed with ADHD and of
being medicated with stimulants.98
There is consensus that the diagnosis of ADHD requires a
specialist, that is, a child psychiatrist, a pediatrician, or other
appropriately qualified health care professionals with train-




Neuropsychological Pathways and Subgroups
ADHD is related to multiple underlying neurobiological
pathways and heterogeneous neuropsychological (NP) pro-
files. Twenty-five years ago, ADHD was characterized as a
disorder of inhibitory self-control,54 and an early dual path-
way model distinguished between an inhibitory/executive
function pathway and a motivational/delay aversion path-
way (also called “cool” and “hot” executive function path-
ways in later publications), which are related to distinct
neurobiological networks.99–101 Still, the two systems may
also interact.102
Since then, other pathways have been added, such as time
processing,103 but a definitive number of possible pathways
is difficult to define. For example, Coghill and colleagues104
differentiated six cognitive factors in children with ADHD
(working memory, inhibition, delay aversion, decision-mak-
ing, timing, and response time variability) derived from
seven subtests of the Cambridge neuropsychological test
automated battery. Attempts to empirically classify patients
into subgroups with selective performance profiles depart-
ing from comprehensive NP data collection were inconclu-
sive. For example, using delay aversion, working memory,
and response-time tasks, Lambek and colleagues105
expected to differentiate corresponding performance profile
subgroups in children with ADHD. However, their analysis
resulted in subgroups differentiated by the severity of
impairments, and not by selective profiles. Other empirical
studies using latent profile or cluster analysis of NP tasks in
large ADHD samples have differentiated three106,107 or
four108 NP profile groups, which all included children with
ADHD, as well as TD children, differing in severity but not in
the type of profile. This might indicate that the identified NP
deficit profiles were not ADHD-specific, but rather reflected
characteristic distributions of NP performances, which are
also present in the general population, with extreme values
in children with ADHD. Some other empirical studies in the
search for subgroups, however, identified ADHD-specific
performance profiles (“poor cognitive control,”109 “with
attentional lapses and fast processing speed”110), among
other profiles being shared with TD controls. Obviously,
divergent results regarding subgrouping may also be related
to differing compilations of tested domains, consequently
leading to a limited comparability of these studies.
Which Neuropsychological Functions are Impaired in
ADHD and When?
A meta-analysis conducted in 2005 identified consistent
executive function deficits with moderate effect sizes in
children with ADHD in terms of response inhibition, vigi-
lance, working memory, and planning.67 Since then, a vast
number of studies on NP deficits in children with ADHD
compared with TD controls have been published. A recent
meta-analysis included 34 meta-analyses on neurocognitive
profiles in ADHD (all ages) published until 2016, referring to
12 neurocognitive domains.111 The authors found that 96% of
all standardized mean differences were positive in favor of
the control group. Unweighted effect sizes ranged from 0.35
(set shifting) to 0.66 (reaction time variability). Weighted
mean effect sizes above 0.50 were found for working memo-
ry (0.54), reaction time variability (0.53), response inhibition
(0.52), intelligence/achievement (0.51), and planning/orga-
nization (0.51). Effects were larger in children and adoles-
cents than in adults. The other domains comprised vigilance,
set shifting, selective attention, reaction time, fluency, deci-
sion making, and memory.
Nearly every neuropsychological domain has been found to
be significantly impaired in ADHDcomparedwith TD controls,
though effect sizes are often small. This includes, for example,
altered perception (e.g., increased odor sensitivity112; altered
sensoryprofile113; impairedyellow/blue color perception, e.g.,
Banaschewski et al,114 for review, see Fuermaier et al115),
emotional tasks (e.g., facial affect discrimination),116 social
tasks (e.g., Marton et al117), communication,118 and
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memory.119 Several of the described impairments may be
related to deficient top-down cognitive control and strategic
deficits,120–122 but there is also evidence for basic processing
deficits.123
Neuropsychological Deficits as Mediators of Gene-
Behavior Relations
A vast amount of research has been devoted to the search for
neuropsychological endophenotypes (or intermediate phe-
notypes) for ADHD, that is, neurobiologically based impair-
ments of NP performance characteristic of the disorder that
may also be found in nonaffected close relatives. ADHD
neuropsychological endophenotypes are assumed to medi-
ate genetic risk from common genetic variants.124 So far,
deficits in working memory, reaction-time variability, inhi-
bition, time processing, response preparation, arousal regu-
lation, and others have been identified as probable
endophenotypes for ADHD.124–127 Genetic studies indicate
an association of an ADHD-specific polygenetic general risk
score (i.e., the total number of genetic variants that may be
associated with ADHD, mostly related to dopaminergic
transmission) with working memory deficits and arousal/
alertness,124 or with a lower intelligence quotient (IQ) and
working memory deficits,128 respectively. More specifically,
a link of ADHD-specific variants of DAT1 genes with inatten-
tion and hyperactivity symptoms seems to be mediated by
inhibitory control deficits.129
Individual Cognitive Profiles and the Relevance of
Cognitive Testing for the Clinical Assessment
Heterogeneity is foundwith regard to profiles, aswell aswith
regard to the severity of cognitive impairment in individuals
with ADHD, as measured by standardized tests. ADHD does
not necessarily come with impaired neuropsychological test
performance: about one-third of children with ADHD will
not present any clinically relevant impairment, while anoth-
er one-third shows unstable or partial clinical impairment,
and about another one-third performs below average in NP
tests. The classic concept of NP impairment, which assumes
relative stability over time, possibly does not apply to NP
deficits observed in ADHD, or only to a lesser extent. For the
larger part, the manifestation of performance deficits may
depend on contextual factors,130 such as reward, or specifi-
cally its timing, amount, and nature, or on energetic fac-
tors,131 for example, the rate of stimulus presentation or the
activation provided by the task.
Many studies have shown that behavioral ratings of ADHD
symptoms or questionnaires on executive function deficits are
not, or at best weakly, correlated with NP test performance,
even when both target the same NP domain.132,133 In conse-
quence, questionnaires on executive functioning are not an
appropriate replacement for neuropsychological testing. Like-
wise, ADHD symptom rating scales do not predict results of
objective attention or executive function tests and vice versa.
Although mild intellectual disability and low IQ are more
typically associated with the disorder, ADHD can be encoun-
tered across the entire IQ spectrum, including highly gifted
children.134Therefore, an intelligence test shouldbepart of the
diagnostic procedure, but isnotmandatoryaccording toADHD
guidelines. In some children, intellectual difficulties and not
ADHD may be the underlying cause for ADHD-like behaviors,
while in other children with ADHD, academic underachieve-
ment despite a high IQ may be present.
It has been argued that symptoms defining ADHDmay be
understood as dimensional markers of several disorders
belonging to an ADHD spectrum and, in consequence, the
diagnosis of these behavioral symptoms should be the start-
ing point for a more in-depth diagnosis rather than the
endpoint.135 This should include the cognitive performance
profile. The ADHD behavioral phenotype predicts neither NP
impairment nor intellectual achievement in the individual
case, and objective testing is the only way to obtain an
accurate picture of the child’s cognitive performance under
standardized conditions. Its goal is not ADHD classification,
but rather to obtain the best possible understanding of the
relation between cognitive functioning and behavioral
symptoms for a given patient, to establish an individually
tailored treatment plan.
Neurophysiology
Neurophysiological methods like EEG, magnetoencephalog-
raphy, and event-related potentials (ERPs) as task-locked EEG
averages capture brain functions in ADHD at high (ms)
temporal resolution. The approach covers both fast and
slow neural processes and oscillations, and clarifies the
type and timing of brain activity altered in ADHD at rest
and in tasks. It reveals neural precursors, as well as corre-
lates, and consequences of ADHD behavior.136 Neurophysio-
logical and particularly EEG measures also have a long and
controversial history as potential biomarkers of ADHD. Cur-
rent evidence clarifies how multiple pathways and deficits
are involved in ADHD at the group level, but recent attempts
toward individual clinical translation have also revealed
considerable heterogeneity, which does not yet support a
clinical application for diagnostic uses or treatment person-
alization, as explained below.
Resting Electroencephalography
The EEG is dominated by oscillations in frequency bands
ranging from slow δ (<4Hz) and θ (4–7Hz) viaα (8–12Hz) to
faster β (13–30Hz) and γ (30–100Hz) band activity. The
spectral profile reflects maturation and arousal, with slow
frequencies dominating during early childhood and slow-
wave sleep. Sourcemodels can link scalp topography to brain
sources and distributed networks.
Initial studies suggested a robust link between ADHD
diagnosis and resting EEG markers of reduced attention,
hypoarousal, or immaturity, such as increased θ and an
increased θ/β ratio (TBR). However,more recent studies,137,138
somewith large samples,139,140 failed to replicate a consistent
TBR increase in ADHD. Instead, the results indicated heteroge-
neous θ and β power deviations in ADHD not explained by
ADHD subtype and psychiatric comorbidity.141 A cluster anal-
ysis of EEG in children with ADHD also revealed considerable
heterogeneity regarding θ excess and β attenuation in ADHD.
While several clusters with EEG patterns linked to
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underarousal and immaturitycouldbe identified, only threeof
the five EEG clusters (60% of the cases with ADHD) had
increased θ.139 Several recent θ and TBR studies that no longer
found TBR associationwithADHDdiagnosis still replicated the
reliable age effects,137,138,142 confirming the high quality of
these studies. Increasing sleepiness in adolescents,143 or
shorter EEG recordings, may have reduced the sensitivity to
time effects and state regulation deficits in ADHD,136,144
potentially contributing to these replication failures. Also,
conceptualizingTBRasamarkerof inattentionormaturational
lag may be too simple, since θ activity can also reflect concen-
tration, cognitive effort, and activation.145,146
During sleep, stage profiles reveal no consistent deviations
in ADHD, but the slow-wave sleep topography is altered. In
particular, frontal slow waves are reduced, leading to a more
posterior topography as observed also in younger children.147
This delayed frontalization can be interpreted as a matura-
tional delay in ADHD, in line with a cluster of resting EEG,
changes in task relatedERPsduringresponse inhibition,148and
structural magnetic resonance imaging (MRI) findings.149
Task Related Event-Related Potentials
Task-related processing measures, particularly ERPs, have
critically advanced our understanding of ADHD through their
high-time resolution, which can separate intact and com-
promised brain functions. ERPs have revealed impairments
during preparation, attention, inhibition, action control, as
well as error, and reward processing, with partly distinct
networks but often present during different phases of the
same task. In youth and adults with ADHD, the attentional
and inhibitory P3 components and the preparatory contin-
gent negative variation (CNV) component are most consis-
tently affected, but state regulation and error or reward
processing are also compromised.136,150 Activity during
preparation, attention, or inhibition is typically weaker
and more variable but not delayed. This often occurs in
task phases without visible behavior and precedes the com-
promised performance. Familial and genetic factors also
modulate these markers of attention and control. Some
impairment is also observed in nonaffected siblings or in
parents without ADHD,151,152 and genetic correlates often
implicate the dopamine system.125 Some ERP changes, like
the attenuated CNV during preparation, remain stable
throughout maturation, and are also markers of persistent
ADHD,while othermarkers, such as the inhibition related P3,
remain attenuated despite clinical remission.148,153
Overall, the ERP results confirm attentional, cognitive, and
motivational, rather than sensory or motor impairments in
ADHD, in line with current psychological and neurobiological
models. However, different ERP studies hardly used the same
tests and measures, so valid statements regarding classifica-
tion accuracy and effect size are particularly difficult,154 and
there is an urgent need for meta-analyses regarding the
different ERPs.
Clinical Translation
Despite published failures to replicate robust TBR based
classification of ADHD, a TBR-based EEG test was recently
approved by the U.S. Food and Drug Administration to assist
ADHD diagnosis.155 Although not promoted as a stand-alone
test, children with suspected ADHD, and increased TBR were
claimed to likely meet full diagnostic criteria for ADHD;
while children with suspected ADHD but no TBR increase
should undergo further testing, as they were likely to have
other disorders better explaining ADHD symptoms (see also
DSM-5 exclusionary criterion E).
This multistage diagnostic approach could possibly iden-
tify a homogeneous neurophysiological subgroup, but it
omits critical elements of careful, guideline-based ADHD
diagnostics. Reliability and predictive value of the TBR
remain untested, and the increasing evidence for poor valid-
ity of TBR renders it unsuitable for stand-alone ADHD
diagnosis. Accordingly, the use of TBR as a diagnostic aid
was broadly criticized.156,157
In sum, the recent literature suggests that neither TBR nor
other single EEG or ERP markers are sufficient to diagnose
ADHD and are not recommended for clinical routine use, in
linewith the increasing evidence for heterogeneity in ADHD.
Combining measures across time, frequency, and tasks or
states into multivariate patterns may better characterize
ADHD. The potential of such approaches is evident in im-
proved classification using machine-learning algorithms
based on combinations of EEG measures142 or EEG and
ERP measures.138,158 However, claims of high-classification
accuracies up to 95% (e.g., Mueller et al158) require further
independent replication and validation with larger samples,
and plausible mapping to neural systems and mechanisms.
Modern pattern classification is particularly sensitive to
uncontrolled sample characteristics and needs validation
through independent large samples.159
Focusing on EEG-based prediction rather than diagnosis
may hold more promise for clinical translation, and may
utilize the EEG heterogeneity in clinical ADHD samples. For
example, early studies on predicting stimulant response
suggested that children with altered wave activity, in partic-
ular increased TBR, θ or α slowing, respond well to stimulant
medication. However, in recent prospective work with a
large sample, TBR was not predictive, and α slowing allowed
only limited prediction in a male adolescent subgroup.160
Predicting response to intense nonpharmacological treat-
ment is of particular interest given the high costs and time
requirements. Promising findings have been reported for one
neurofeedback study, where α EEG activity and stronger CNV
activity together predicted nearly 30% of the treatment
response.161 Still, the lackof independent validation current-
ly allows no clinical application.
In conclusion, neurophysiological measures have clarified
a rich set of distinct impairments but also preserved func-
tions which can also serve as markers of persistence or risk.
These markers may also contribute in the classification of
psychiatric disorders based on neuromarkers (research do-
main criteria approach). As potential predictors of treatment
outcome theymay support precisionmedicine, and proof-of-
concept studies also highlight the potential of multivariate
profiling. The findings also demonstrate the challenge with
this approach, including notable replication failures, and
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generalizability of most findings remains to be tested.
Neurophysiological markers are not ready to serve as tools
or aids to reliably diagnose ADHD, or to personalize ADHD
treatment in individual patients.
Neuroimaging
Modern brain imaging techniques have critically contributed
to elucidating the etiology of ADHD. While MRI provides
detailed insights into the brain microstructure, such as for
example gray matter volume, density, cortical thickness, or
white matter integrity, fMRI allows insights into brain func-
tions through activation and connectivity measures with
high–spatial resolution.
Delayed Maturation and Persistent Alterations in the
Brain Microstructure in ADHD
Thebrainundergoespronounceddevelopmental alterations in
childhood and adolescence. Gray matter volume and cortical
thickness show nonlinear inverted U-shaped trajectories of
maturation with a prepubertal increase followed by a subse-
quent decrease until adulthood while white matter volume
progressively increases throughout adolescence and early
adulthood in a rather linear way.162–165 Large variations of
the maturational curves in different brain regions and sub-
regions suggest that phylogenetically older cortical areas
mature earlier than the newer cortical regions. Moreover,
brain areas associated with more basic motor or sensory
functions mature earlier than areas associated with more
complex functions including cognitive control or atten-
tion.163,164 Altered maturation of the cortex for ADHD has
been reported for multiple areas and cortical dimen-
sions,166,167 mainly in the form of delayed developmental
trajectories inADHDbut recentlyalso aspersistent reductions,
particularly in the frontal cortex.168 Such findings speak for
delayed maturation in specific areas rather than a global
developmental delay of cortical maturation in ADHD. Micro-
structural alterations in ADHD have been associated with a
decreased intracranial volume169 and total brain size reduc-
tion of around 3 to 5%.100,168,170 In accordance, increasing
ADHD symptoms in the general population correlated nega-
tively with the total brain size.171 Ameta-analysis (Frodl et al)
and a recent cross-sectional mega- and meta-analysis (Hoog-
man et al) indicate that such reductions in brain volume may
bedue to decreasedgraymatter volumes in several subcortical
structures, such as the accumbens, amygdala, caudate, hippo-
campus, and putamen but also cortical areas (prefrontal, the
parietotemporal cortex) and the cerebellum.170,172–177 Effects
sizes of subcortical alterations were highest in children with
ADHD and the subcortical structures showed a delayedmatu-
ration.169Moreover, higher levels of hyperactivity/impulsivity
in children were associated with a slower rate of cortical
thinning inprefrontal and cingulate regions.167,178Differences
in brain microstructure have also been reported in a meta-
analysis for whitematter integrity asmeasuredwith diffusion
tensor imaging in tracts subserving the frontostriatal-cerebel-
lar circuits.179 To summarize, diverse neuroanatomical alter-
ations in total brain volume and multiple cortical and
subcortical dimensions characterize ADHD. These alterations
are most pronounced in childhood and suggest a delayed
maturation of specific cortical and subcortical areas along
with some persistent reductions in frontal areas in a subgroup
of ADHD patients with enduring symptoms into adulthood.
Alterations in the Brain Function of Specific Networks in
ADHD
Specific functional networks, mainly those involved in inhibi-
tion, attentionprocesses, cognitive control, reward processing,
workingmemory, or during rest have been intensively studied
inADHDusing fMRI in thepast. Alterationshavebeen reported
in the correspondingbrainnetworks and themainfindings are
summarized below.
Atypical Resting State Connectivity in Children with
ADHD
Resting state examines spontaneous, low frequency fluctua-
tions in the fMRI signal during rest, that is , in absence of any
explicit task.180 Resting state networks describe multiple
brain regions for which the fMRI signal is correlated (func-
tionally connected) at rest, but the same networks may
coactivate also during task-based fMRI.181 One important
resting state network, the so-called default mode network
(DMN), comprises brain areas that show higher activation
during wakeful rest and deactivations with increasing atten-
tional demands.182,183 While the DMN usually shows de-
creasing activationwith increasing attentional demands, the
cognitive control network shows an opposite pattern and
increases its activation. This inverse correlation of DMN and
the cognitive control networks is diminished or absent in
children and adults with ADHD and may explain impaired
sustained attention through attentional lapses that are me-
diated by the DMN.181,184–186 In addition, a more diffuse
pattern of resting state networks connectivity and a delayed
functional network development in children with ADHD
have been reported.187 Finally, atypical connectivity in cog-
nitive and limbic cortico-striato-thalamo-cortical loops of
patients with ADHD suggest that the neural substrates may
either reside in impaired cognitive network and/or affective,
motivational systems.181
Altered Processing of Attention and Inhibition in
Fronto-basal Ganglia Circuits in ADHD
Meta-analyses summarizing the findings of functional activa-
tion studies report most consistent alterations in brain activa-
tion patterns as hypoactivation of the frontoparietal network
for executive functions and the ventral attention system for
attentional processes in children with ADHD.188–190 More
specifically, motor or interference inhibition tasks yielded
consistent decreases in a (right lateralized) fronto-basal gan-
glia network comprising supplementary motor area, anterior
cingulate gyrus, left putamen, and right caudate in children
with ADHD.189,190 For tasks targeting attentional processes,
decreased activation in a mainly right lateralized dorsolateral
fronto-basal ganglia-thalamoparietal network characterized
children with ADHD. Depending on the task, hyperactivation
can cooccur in partly or distinct cerebellar, cortical, and
subcortical regions.188–190
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Altered Reward Processing and Motivation
Emotion regulation and motivation is mediated by extended
orbitomedial and ventromedial frontolimbic networks in the
brain.191 Abnormal sensitivity to reward seems to be an
important factor in the etiology of ADHD as suggested by
several models of ADHD,192–194 mainly due to a hypofunc-
tioning dopaminergic system.195 In accordance, impair-
ments in specific signals that indicate violations of
expectations, the so called reward prediction errors (RPE),
were shown in the medial prefrontal cortex of adolescents
with ADHD during a learning task.196 RPE signals are known
to be encoded by the dopaminergic system of the brain, and
deficient learning and decisionmaking in ADHDmay thus be
a consequence of impaired RPE processing.196 Abnormal
activation has also been reported for the ventral striatum
during reward anticipation and in other cortical and subcor-
tical structures of the reward circuitry.197
Normalization of Atypical Activation and Brain Structural
Measures after Treatment
Stimulant medication and neurofeedback studies have
pointed to a certain normalization of dysfunctional activa-
tion patterns in critical dorsolateral frontostriatal and orbi-
tofrontostriatal regions along with improvements in ADHD
symptoms.198–201 Also, brain microstructure, especially the
right caudate, has shown some gradual normalization with
long-term stimulant treatment.176,190
To conclude, a wide range of neuroimaging studies reveal
relatively consistent functional deficits in ADHD during
executive functions, including inhibitory control, working
memory, reward processes, and attention regulation but also
during rest. Some of these alterations are more persistent,
others are specific to children and may thus represent a
developmental delay. Specific treatments showed trends
toward a normalization of alterations in brain microstruc-
ture and functional networks.
Genetic Associations with ADHD and ADHD Related
Traits
From family studies, as well as twin studies, the heritability
for ADHD has been estimated to be between 75 upto 90%.202
Moreover, the heritability was found to be similar in males
and females and for inattentive and hyperactive-impulsive
components of ADHD.202 Interestingly, a strong genetic
component was also found when the extreme and sub-
threshold continuous ADHD trait symptoms were assessed
in the Swedish twins.19 Even over the lifespan, adult ADHD
was found to demonstrate high heritability that was not
affected by shared environmental effects.203 Recently, struc-
tural and functional brain connectivity assessed in families
affected by ADHD has been shown to have heritable compo-
nents associated with ADHD.204 Similarly, the heritability of
ERPs elicited in a Go/No-Go-task measuring response inhi-
bition known to be altered in ADHD, was found to be
significantly heritable.205
In several studies, ADHD-related traits have also shown
significant heritability. For example, in two independent,
population based studies, significant single nucleotide poly-
morphism heritability estimates were found for attention-
deficit hyperactivity symptoms, externalizing problems, and
total problems.206 In another study, investigating the two
opposite ends of ADHD symptoms, low-extreme ADHD traits
were significantly associated with shared environmental
factorswithout significant heritability.207While on the other
hand, high-extreme ADHD traits showed significant herita-
bility without shared environmental influences.207 A cross-
disorder study including 25 brain disorders from genome
wide association studies (GWAS) of 265,218 patients and
784,643 controls, including their relationship to 17 pheno-
types from 1,191,588 individuals, could demonstrate signif-
icant shared heritability.208 In particular, ADHD shared
common risk variants with bipolar disorder, major depres-
sive disorder, schizophrenia, and with migraine.208 Indeed,
in general, population-based twin studies suggest that ge-
netic factors are associatedwith related-population traits for
several psychiatric disorders including ADHD.209 This sug-
gests that many psychiatric disorders are likely to be a
continuous rather than a categorical phenotype.
Though ADHDwas found to be highly heritable, the under-
lying genetic risk factors are still not fully revealed. The current
consensus suggests, as in many other psychiatric disorders, a
multifactorial polygenic nature of the common disorder. Both
commongenetic variants studied by hypothesis-driven candi-
date gene association or by the hypothesis-free GWAS could
only reveal the tip of the iceberg. Through the candidate gene
approach, only very few findings could show replicable signif-
icant association with ADHD, as reported by meta-analysis
studies for the dopaminergic, noradrenergic, and serotonergic
genes.210,211 Several GWAS have been conducted followed by
meta-analysis, which again failed reaching genome-wide sig-
nificant results.212–224 However, recently, the first genome-
wide significance has been reached in a GWAS meta-analysis
consisting of over 20,000 ADHD patients and 35,000 con-
trols.225 Twelve independent loci were found to significantly
associate with ADHD, including genes involved in neurodeve-
lopmental processes, such as FOX2 and DUSP6.225 But even in
these findings the effect sizes are rather small to be used for
diagnostic tools. Therefore, polygenic risk score approaches
have emerged as a possible tool to predict ADHD.202 Yet this
approach needs further investigation now that genome-wide
significance has been reached by Demontis et al.225 However,
at this point, it is not yet possible to exclude that rare SNPs of
strong effectmayalso be responsible (similar to breast cancer)
for a small proportion of ADHD cases due to the heterogeneity
of symptomatology, illness course, aswell as biologicalmarker
distribution, as outlined above.
Treatment
Multimodal Treatment of ADHD
A variety of national and international guidelines on the
assessment and management of ADHD have been published
over the last 10 years, not only for clinicians but also for
patients and caregivers.96,97,226–228 All guidelines recom-
mend a multimodal treatment approach in which psycho-
education forms a cornerstone of the treatment and should
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be offered to all of those receiving an ADHDdiagnosis, as well
as to their families and caregivers.
According to the NICE Guidelines, the first step is always a
planningprocess for themultimodal treatmentwith respect to
the psychological, behavioral, and occupational or educational
needs of the child and his/her family.97 This planning phase
could be organized as a “round table” with the child, parents,
and other caregivers. The following aspects should be taken
into account: the severity of ADHD symptoms and im-
pairment, the relative impact of other neurodevelopmental
ormental health conditions and how these affect ormayaffect
everyday life (including sleep). In addition, resilience and
protective factors, as well as the goals of the child and family,
should be considered in the intervention process. The partici-
pation of child and parents in the planning and treatment
process is more centrally outlined in recent guidelines and is
emphasized in detail for the different treatment steps (e.g.,
NICE and S3 Guidelines).96,97 The participation process is not
just a one-time dialogue but should rather continue through-
out all steps of the treatment process. Benefits and harms of
nonpharmacological and pharmacological treatments should
be discussed carefully and on the basis of the latest evidence.
Preferences and concerns, and the importance of adherence to
treatment, should be discussed and taken into account within
the treatment process. Patients and their families or caregivers
should be reassured, as appropriate that they can revisit
decisions about treatments.
Multimodal treatment approaches also advocate a system-
atic adaptive procedure that combines different treatment
modules according to the needs and situation of the patient
and family. Thismay, for instance, include afirst stage inwhich
parent counseling is initiated, a second-stage encompassing,
for example, individual behavioral therapy for the child, while
theparentsparticipate in aparent training program inparallel,
followed by a third stage in which stimulant medication is
started, etc.229,230 Environment-centered interventions aim at
the counseling or training of parents or the instruction of
teachers at school or preschool. Parent training programsmay
be administered individually or in groups and have shown
positive effects on parenting skills, ADHD behavior, and co-
morbid conduct problems.231–233 Family therapy for ADHD
focuses on the ADHD family, with the ADHD patient being a
part of the family system with dysfunctional interactional
patterns.234 School-based interventions may target (1) the
conditions in the classroom, for example, by minimizing
distractions; (2) the instruction of the teacher, for example,
by suggesting more appropriate teaching methods or by
promoting peer tutoring; or (3) the student, for example, by




All medication for ADHD should only be initiated by a health
care professional with training and expertise in diagnosing
and managing ADHD. The expert should be familiar with the
pharmacokinetic profiles and bioavailability of all the short-
and long-acting preparations available for ADHD. The fol-
lowing parameters should be considered before first medi-
cation: medical history of the child but possibly also of the
parents, current medication, height and weight, baseline
pulse and blood pressure, a cardiovascular assessment, and
an electrocardiogram if the treatment may affect the QT
interval. A cardiology expert opinion should be sought before
startingmedication for ADHD if there is a history of congeni-
tal heart disease, previous cardiac surgery, or a history of
sudden death in a first-degree relative under the age of 40
years, or if the blood pressure is consistently above the 95th
centile for age and height for children and young people.
Age-Specific Needs
Treatment recommendations are often based on the specific
needs of children, youth, or adults.97,226 According to the
NICE guidelines97 and also pharmacological recommenda-
tions (e.g., Walitza and colleagues238,239), a distinction
should also be made between children under 5 years of
age or preschool children, and school children. For the
younger children (under 5 years of age), parent or career
training programs and parent group training programs are
always first-line treatments. Medication for children under 5
years with ADHD should only be given following a second
specialist opinion from an ADHD service with expertise in
managing ADHD in young children (ideally from a tertiary
service). For children over 5 years of age, education and
information about the causes and impact of ADHDand advice
on parenting strategies should be offered, as well as liaison
with school, college, or university if consent to do so is
provided.97 Children aged 5 years and over and young people
should only receive medication if the ADHD symptoms are
still causing a persistent significant impairment in at least
one life domain after environmentalmodifications havebeen
implemented and evaluated.
Selection of Pharmacotherapy
In Europe, methylphenidate either as short- or long-acting
preparation is the first-line medication for ADHD across the
life span. Second-line medications are lisdexamfetamine,
atomoxetine, and guanfacine. A switch to lisdexamfetamine
is only recommended if children havefirst undergone at least
a 6-week trial of methylphenidate at an adequate dose and
have not derived sufficient benefit in terms of reduced ADHD
symptoms and associated impairment, or if patients experi-
ence adverse side effects.238 The Canadian Guidelines (2018)
recommend an individual treatment approach, which can
start with different options, and if medication is to be used,
long-acting formulations of psychostimulants or atomoxe-
tine are always the first choice.226 Comorbid disorders may
necessitate adjustments to the treatment plan or alternative
treatments.
According to the NICE guidelines, atomoxetine and guan-
facine should only be offered if patients cannot tolerate
methylphenidate or lisdexamfetamine or if their symptoms
have not responded to separate 6-week trials of methylphe-
nidate and lisdexamfetamine, having considered alternative
preparations and adequate doses.97
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Evidence for ADHD Medications
In the first “gold standard” study comparing the different
treatment approaches for ADHD alone and in combination
(National Institute of Mental Health Collaborative Multi-
modal Treatment Study of Children with ADHD [MTA
study]), the effects of both pharmacological therapy (meth-
ylphenidate and intensive counseling) and of multimodal
therapy (methylphenidate and intensive behavioral therapy)
were significantly more effective after 14 months than
behavioral therapy alone or than the “standard” therapy
(treatment as usual in the community) of the control group.
The multimodal therapy was not significantly superior to
pharmacological therapy alone, but did result in significant
improvements in ADHD symptoms at a lower dosage of
methylphenidate.240–242 Since the MTA study, numerous
studies have investigated methylphenidate, amphetamine,
and nonstimulants like atomoxetine or α2-adrenoceptor
agonists, such as clonidine and guanfacine, regarding differ-
ent aspects of effectiveness and tolerability.
The psychostimulants methylphenidate and amphet-
amine are the most effective agents for the treatment of
core ADHD symptoms, with a favorable efficacy and adverse
event profile.243–245 Compared with methylphenidate and
amphetamine, which both show immediate symptom reduc-
tion, the full effects of atomoxetine and guanfacine on
reducing ADHD symptoms usually only unfold after some
weeks of administration. Atomoxetine and guanfacine are
not controlled substances, and are licensed in various Euro-
pean countries and in the United States for treatment of
ADHD in children above the age of 6 years. Both have been
shown to be effective in decreasing ADHD core symptoms
with an effect size of around 0.7, which is somewhat lower
than the effect size for methylphenidate, depending on the
underlying studies (e.g., Sallee et al246).
Management Strategies and Duration of Pharmacological
Treatment
Following an adequate dosage of medication (►Table 1) and
treatment response, medication for ADHD should be titrated
to an optimized dosage with regard to the clinical efficacy,
safety, and side effects, which should be continued for as long
as it remains clinically necessary and effective. This should be
reviewed at least annually, also with a planned “medication
break” to decide whether there is a continuing need for
care.238,239 However, there is little available empirical evi-
dence to guide clinicians on questions, such as the optimum
duration of treatment and when it is appropriate to consider
drug discontinuation. As ADHD can persist into adulthood,
decisions on treatment discontinuation need to be taken on a
case-by-case basis.226
Among the most frequent side effects of psychostimulant
therapy (►Table 2) are reduced appetite and sleep distur-
bances.247 Appetite reduction following treatment initiation
with an ADHD drug often attenuates with time. Reduced
appetite at mealtimes can be avoided by taking the medica-
tion after meals rather than before. Should a clinically
Table 1 Dosage recommendation for the most commonly used psychostimulants and other medications in the treatment of
children and adolescents with ADHD




Number of doses per day
Methylphenidate immediate release 0.3– max. 1.0 5–40 1–3
Ritalin Medikinet Max.: 60








Amphetamine Liquid 0.1–0.5 2.5–20 1–2 (3)
max. 40
Lisdexamphetamine 30–70 1
Atomoxetine 0.5–0.8; max.1.2 If less than 70 kg: 1–2
Strattera 18–60
if more than 70 kg:
40–max. 100
Guanfacine extended release 0.05–0.12 1–4 1
Intuniv

Without any reason the dose should not be increased above 60 mg.
Abbreviations: ADHD, attention deficit hyperactivity disorder; max. maximum.
Adapted from (1) Walitza S, Romanos M, Greenhill LL, Banaschewski T. Attention-Deficit/Hyperactivity Disorders. In: Gerlach M, Warnke A, Greenhill
LL, eds. Psychiatric Drugs in Children and Adolescents. Wien: Springer; 2014:369–381238 and (2) Walitza S, Gerlach M, Romanos M, Renner T.
Psychostimulanzien und andere Arzneistoffe, die zur Behandlung der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) angewendet werden.
In: Gerlach M, Mehler-Wex C, Walitza S, Warnke A, Wewetzer C, eds. Neuro-/Psychopharmaka im Kindes- und Jugendalter: Grundlagen und Therapie.
Berlin, Heidelberg: Springer Berlin Heidelberg; 2016:289–331.239
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significant lack of appetite persist, dosage reduction (by one-
fourth or half tablet of methylphenidate), discontinuation
(rarely necessary), or switching to a different formulation or
medication should be considered.
Nonpharmacological Treatments
Cognitive Behavioral Therapy
Cognitive behavioral therapy (CBT) is a form of behavioral
intervention which aims at reducing ADHD behaviors or
associated problems by enhancing positive behaviors and
creating situations in which desired behaviors may occur. In
the case of preschool and young school children, CBT focuses
on parents and educators, who are instructed and trained to
act according to CBT principles, while older children and
adolescents may be trained directly to use more appropriate
behavioral strategies.248 CBT and its more specific forms (e.
g., social skills training, training of planning and organiza-
tional skills, and self-management techniques) have positive
effects on behavior, parenting skills, child–parent relation-
ships, and certain daily living skills,232,249 although effects on
ADHD core symptoms are inconsistent and relatively low
when only blinded assessments are considered.250 A recent
meta-analysis suggested that the combined treatment of
medication with CBT is more efficacious than stimulant
medication alone (with an estimated standardized mean
difference of 0.5).251
Neuropsychological Treatments
In cognitive training interventions, either PC-supported or in
a manualized format, cognitive exercises that tap into cogni-
tive domains, such as workingmemory or inhibitory control,
are performed in a repetitive manner and with increasing
difficulty. The evidence base for this type of intervention is
poor according to recent studies (e.g., Bikic et al252) and
metastudies (e.g., Cortese et al253). While some “near-trans-
fer” improvements in neuropsychological tests tapping into
the trained domain are probable, the evidence for “far
transfer” to academic achievements or to the ADHD symp-
tom level is weak. Most studies, however, used the same kind
of cognitive training with all participants, irrespective of
their actual individual cognitive difficulties. Moreover, they
did not adhere to theoretically based training principles,
which recommend domain-specific training for the func-
tional improvement of a selective neuropsychological deficit.
Possibly, future approaches that combine repetitive exercise
and top-down strategy application may provide larger ben-
efits for children with ADHD.
In neurofeedback training (NF), EEG activity measured by
one or more electrodes applied to the head is transformed
into a visual or acoustic signal and fed back online, for
example, by a stimulus moving up and down. By steering
the stimulus on the screen, the participant may gain control
over his/her EEG activity. Many different training protocols
have been applied to ADHD. Those which have received the
best evaluation are the NF training of the θ/β frequency
bands ratio (the goal is generally to decrease θ and to
increase β frequencies) and the training of slow cortical
potentials (learning to intentionally increase and decrease
cortical excitability over short periods of time). However,
“normalizing” an ADHD-specific deviant EEG pattern can no
longer qualify as a meaningful goal, as no characteristic
ADHD pattern seems to exist (Loo et al,254 see neurophysiol-
ogy section), although gaining control over one’s brain
activity and over attentional states continues to be a valid
treatment goal. According to parent ratings, clinical improve-
ments after NF are stronger and longer-lasting compared
with other behavioral treatment methods, but teacher rat-
ings usually fail to yield significant effects.255 Recent re-
search has focused on the specificity of treatment effects,
Table 2 Adverse drug reactions for psychostimulants and other medications in the treatment of children and adolescents with
attention deficit hyperactivity disorder




decreased appetite, insomnia or sleep disturbance, snoring, non-breathing or gasping while
sleeping, sleepwalking, various sleep positions, enuresis, talking to sleep, number of hours of
sleep, number of nocturnal movements, sleep quality, stomach upset, dizziness, headache,
irritability, nausea, vomiting, tachycardia, increased blood pressure, moodiness, weight loss
(higher dose), psychotic disorder, arrhythmias
Amphetamine
(different formulations)
appetite suppression, weight loss, insomnia, stomach aches, headaches, irritability, dizziness,
possible growth inhibition, exacerbation of psychosis, and tics, and possible increase in blood
pressure and pulse
Atomoxetine headache, nausea, abdominal pain, decreased appetite, moodiness and somnolence
Guanfacine somnolence, sedation, headache, upper abdominal pain, and fatigue
Adapted from (1) Walitza S, Romanos M, Greenhill LL, Banaschewski T. Attention-Deficit/Hyperactivity Disorders. In: Gerlach M, Warnke A, Greenhill
LL, eds. Psychiatric Drugs in Children and Adolescents. Wien: Springer; 2014:369–381238; (2) Walitza S, Gerlach M, Romanos M, Renner T.
Psychostimulanzien und andere Arzneistoffe, die zur Behandlung der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) angewendet werden.
In: Gerlach M, Mehler-Wex C, Walitza S, Warnke A, Wewetzer C, eds. Neuro-/Psychopharmaka im Kindes- und Jugendalter: Grundlagen und Therapie.
Berlin, Heidelberg: Springer Berlin Heidelberg; 2016:289–331239; (3) Huang YS, Tsai MH. Long-term outcomes withmedications for attention-deficit
hyperactivity disorder: current status of knowledge. CNS Drugs 2011;25:539–554; (4) Storebo OJ, Pedersen N, Ramstad E et al. Methylphenidate for
attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomized studies. Cochrane
Database Syst Rev 2018;5:CD012069284; and (5) Wigal T, Greenhill L, Chuang S et al. Safety and tolerability of methylphenidate in preschool
children with ADHD. J Am Acad Child Adolesc Psychiatry 2006;45:1294–1303.
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defined as the association between the learned regulation of
EEG activity and the behavioral outcome.256 To date, there is
no convincing evidence that the learned control over brain
activity is responsible for the observed behavioral improve-
ments. Instead, nonspecific treatment effects, such as im-
proved self-efficacy, positive reinforcement, and learning to
sit still, seem to contribute in large part to the positive
clinical outcome.
Methodologically more sophisticated NF approaches,
such as tomographic NF,257 fMRI-NF,258 or near-infrared
spectroscopy feedback (feedback of hemoglobin oxygen-
ation)259 are still in the experimental stage.
Noninvasive Brain Stimulation
Repetitive transcranial magnetic stimulation (TMS) and
transcranial direct current stimulation (tDCS) represent
other potential means to modulate cortical activity. There-
fore, these approaches may also be promising in terms of
improving clinical and cognitive ADHD symptoms such as
inattention and impulsiveness.258,260–262 Based on a meta-
analysis, Westwood et al263 suggested that left and/or right
prefrontal stimulation may improve performance in atten-
tion, inhibition and/or working memory tasks. However,
these approaches are not yet recommended by therapy
guidelines.
Alternative Nonpharmacological Treatment Methods
Mindfulness training, physical activity, and yoga seem to
have positive effects on ADHD behavior, but for the time
being, the scientific evidence is weak and these treatments
are seen at best as complementary to other interven-
tions.264–268 Digital home treatment programs or support
apps are currently being developed for ADHD patients or
their parents269,270; their usefulness or clinical validity still
needs to be tested. Children and adolescents with ADHD
often show a great affinity with digital media, which may
improve compliance, but onehas to take into account that the
rate of problematic internet use and gaming is enhanced in
youth with ADHD (estimated at 37% in ADHD vs. 12% in
TD).271 Free fatty acid supplementation has been described
to bring about small but significant reductions in ADHD
symptoms even with probably blinded assessments (stan-
dardized mean difference¼0.16).250
Long-Term Outcome
Follow-up studies have reported divergent results, with
some reporting high rates of persistence until adulthood
(up to 79%),153 and others showing much higher rates of
remission from childhood to adolescence (e.g., 45–55% of
syndromal remissions).272–274 Recent population-based
studies from Brazil, the United Kingdom, and New Zealand
have claimed that a large portion of de novo ADHD cases
emerge at adult age,275–277 but these results can probably be
explained by methodological artifacts and missed sub-
threshold cases.76,278,279 However, meta-analytic findings
by Bonvicini et al280 indicate that in part, different genes and
polymorphisms seem to contribute to childhood ADHD and
adulthood ADHD, lending some genetic plausibility to find-
ings of a late manifestation of the disorder. According to the
MTA study, the contribution of interventions administered
during childhood to outcome in adulthood is negligible, but
controlled intervention was limited to a relatively short
period of time (14 months).281 Neurobiologically, the course
of ADHDmay be explained by different models.274According
to the first model, remission at adult age may be reduced to
the normalization of brain functions through maturation. A
secondmodel explains remission through the recruitment of
compensatory brain functions. The third model claims that
brain function anomalies show life-long persistence, even
though behavioral dysfunction may have remitted.274 Possi-
bly, all of thesemodels, and probably additional ones too (see
e.g., Doehnert et al148), apply to different subgroups of
patients or functions and may account for the divergent
results in the literature.
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